OOIR: Observatory of International Research

Papers

(The H4-Index of Lung Cancer is 34. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
The evolving landscape of biomarker testing for non-small cell lung cancer in Europe	125
Lung cancer prediction by Deep Learning to identify benign lung nodules	93
Real-world outcomes of immunotherapy–based regimens in first-line advanced non-small cell lung cancer	77
Vaping and lung cancer – A review of current data and recommendations	71
Going beneath the tip of the iceberg. Identifying and understanding EML4-ALK variants and TP53 mutations to optimize treatment of ALK fusion positive (ALK+) NSCLC	65
Association of baseline peripheral-blood eosinophil count with immune checkpoint inhibitor-related pneumonitis and clinical outcomes in patients with non-small cell lung cancer receiving immune checkp	64
Erlotinib plus bevacizumab vs erlotinib monotherapy as first-line treatment for advanced EGFR mutation-positive non-squamous non-small-cell lung cancer: Survival follow-up results of the randomized JO	63
Treatment strategies and outcomes for patients with EGFR-mutant non-small cell lung cancer resistant to EGFR tyrosine kinase inhibitors: Focus on novel therapies	60
Biomarker testing in non-small cell lung cancer in routine care: Analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315)	56
Relationship between podoplanin-expressing cancer-associated fibroblasts and the immune microenvironment of early lung squamous cell carcinoma	53
Temporal trends of the lung cancer mortality attributable to smoking from 1990 to 2017: A global, regional and national analysis	50
KRAS G12C-mutated advanced non-small cell lung cancer: A real-world cohort from the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315)	50
Neoadjuvant anti-programmed death-1 immunotherapy by pembrolizumab in resectable non-small cell lung cancer: First clinical experience	49
KRAS G12D mutation predicts lower TMB and drives immune suppression in lung adenocarcinoma	46
Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer: 2-year follow-up from a randomized, open-label, phase 3 study (Che	45
Combination atezolizumab, bevacizumab, pemetrexed and carboplatin for metastatic EGFR mutated NSCLC after TKI failure	44
Antibody-drug conjugates: A promising novel therapeutic approach in lung cancer	43
The rapidly evolving landscape of novel targeted therapies in advanced non-small cell lung cancer	43
Durvalumab after definitive chemoradiotherapy in locally advanced unresectable non-small cell lung cancer (NSCLC): Real-world data on survival and safety from the German expanded-access program (EAP)	43
Biomarker testing and tissue journey among patients with metastatic non-small cell lung cancer receiving first-line therapy in The US Oncology Network	42
Surprising impact of stromal TIL’s on immunotherapy efficacy in a real-world lung cancer study	42
Calculated indices of volatile organic compounds (VOCs) in exhalation for lung cancer screening and early detection	40
Survival outcomes in a prospective randomized multicenter Phase III trial comparing patients undergoing anatomical segmentectomy versus standard lobectomy for non-small cell lung cancer up to 2 cm	39
Thromboembolism in ALK+ and ROS1+ NSCLC patients: A systematic review and meta-analysis	37
Durable responses to immunotherapy of non-small cell lung cancers harboring MET exon-14–skipping mutation: A series of 6 cases	37

Real-world survey of pneumonitis and its impact on durvalumab consolidation therapy in patients with non-small cell lung cancer who received chemoradiotherapy after durvalumab approval (HOPE-005/CRIMS	37
Genomic alterations and clinical outcomes in patients with lung adenocarcinoma with transformation to small cell lung cancer after treatment with EGFR tyrosine kinase inhibitors: A multicenter retrosp	36
European Cancer Organisation Essential Requirements for Quality Cancer Care (ERQCC): Lung cancer	36
A phase I/II study of osimertinib in EGFR exon 20 insertion mutation-positive non-small cell lung cancer	35
Clinical impact of pembrolizumab combined with chemotherapy in elderly patients with advanced non-small-cell lung cancer	35
Osimertinib for Chinese advanced non-small cell lung cancer patients harboring diverse EGFR exon 20 insertion mutations	35
Identification of a novel gene expression signature associated with overall survival in patients with lung adenocarcinoma: A comprehensive analysis based on TCGA and GEO databases	35
Effectiveness and safety of immunotherapy in NSCLC patients with ECOG PS score ≥2 – Systematic review and meta-analysis	34
Tobacco exposure and immunotherapy response in PD-L1 positive lung cancer patients	34
A retrospective observational study of the natural history of advanced non–small-cell lung cancer in patients with KRAS p.G12C mutated or wild-type disease	34
NTRK fusions in lung cancer: From biology to therapy	34
Stromal FAP is an independent poor prognosis marker in non-small cell lung adenocarcinoma and associated with p53 mutation	34